Comparison 2. HAART + pegylated liposomal doxorubicin versus HAART alone (RCT).
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Clinical response | 1 | 10 | Risk Ratio (M-H, Fixed, 95% CI) | 9.0 [0.61, 133.08] |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.